| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
|
N Engl J Med
|
2004
|
49.02
|
|
2
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
3
|
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
|
J Clin Oncol
|
2002
|
13.81
|
|
4
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
|
5
|
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2003
|
8.95
|
|
6
|
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
|
J Clin Oncol
|
2004
|
7.87
|
|
7
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
|
8
|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
5.81
|
|
9
|
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
|
J Clin Oncol
|
2005
|
5.27
|
|
10
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
11
|
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
|
J Clin Oncol
|
2010
|
4.81
|
|
12
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
|
13
|
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
4.68
|
|
14
|
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
|
J Clin Oncol
|
2005
|
4.66
|
|
15
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
16
|
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
|
J Clin Oncol
|
2005
|
4.45
|
|
17
|
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
|
J Clin Oncol
|
2010
|
4.43
|
|
18
|
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
|
Breast Cancer Res
|
2006
|
4.28
|
|
19
|
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
|
J Clin Oncol
|
2010
|
4.23
|
|
20
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
21
|
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
|
J Clin Oncol
|
2008
|
3.66
|
|
22
|
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
|
Breast Cancer Res Treat
|
2010
|
3.35
|
|
23
|
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
|
J Clin Oncol
|
2013
|
3.18
|
|
24
|
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
|
J Clin Oncol
|
2007
|
3.05
|
|
25
|
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
2.93
|
|
26
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
|
Lancet Oncol
|
2012
|
2.65
|
|
27
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
28
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
|
29
|
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
|
J Surg Oncol
|
2005
|
2.47
|
|
30
|
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
|
J Clin Oncol
|
2009
|
2.34
|
|
31
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
32
|
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
|
J Clin Oncol
|
2012
|
2.19
|
|
33
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
34
|
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
|
J Clin Oncol
|
2013
|
1.81
|
|
35
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
|
36
|
Organizational barriers to physician participation in cancer clinical trials.
|
Am J Manag Care
|
2005
|
1.56
|
|
37
|
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
1.20
|
|
38
|
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
|
Clin Cancer Res
|
2012
|
1.17
|
|
39
|
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
|
Breast Cancer Res Treat
|
2011
|
1.16
|
|
40
|
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
|
Invest New Drugs
|
2007
|
1.01
|
|
41
|
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.00
|
|
42
|
Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.
|
J Clin Oncol
|
2010
|
0.89
|
|
43
|
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
|
Breast Cancer Res
|
2013
|
0.86
|
|
44
|
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
|
J Thorac Oncol
|
2014
|
0.79
|
|
45
|
Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.
|
J Oncol Pract
|
2013
|
0.77
|
|
46
|
Use of raloxifene among women with a history of breast cancer.
|
Breast Cancer Res Treat
|
2006
|
0.75
|
|
47
|
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
|
Pancreas
|
2016
|
0.75
|